Analytical Data
-
Gene name
VACWR087
- Application
-
Alternative Names
(Protein F1)
-
Species
Vaccinia virus
-
Source
Yeast
-
Tag
C- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P07611
-
Expression Region
2-319aa
-
Molecular Weight
37.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
VACWR087 is a recombinant protein derived from the Vaccinia virus, which has garnered significant interest in the field of immunology and vaccine development. This protein is believed to play a critical role in modulating the host's immune response, thereby enhancing the understanding of viral pathogenesis and the development of effective therapeutics. The Vaccinia virus, being a member of the Orthopoxvirus genus, has been widely studied due to its historical use as a live vaccine against smallpox and its potential for use in oncolytic virology. Research on VACWR087 focuses on its interactions with host immune mechanisms, particularly how it may inhibit inflammatory pathways or manipulate cellular responses to improve viral survival and replication. Additionally, the potential application of VACWR087 in novel vaccine platforms offers a promising avenue for developing vaccines against other infectious diseases and cancers. Ongoing studies aim to elucidate the detailed biochemical pathways influenced by VACWR087, advancing both basic virology and translational medicine. This research not only contributes to the understanding of the Vaccinia virus but may also pave the way for innovative strategies in immune modulation and therapeutic interventions.
